SpringerLink
Log in

Risk Assessment for Diabetes

  • Chapter
  • First Online:
Risk Assessment in Oral Health

  • 694 Accesses

Abstract

Type 2 diabetes is a serious chronic condition that may go undetected and therefore untreated for many years. Therefore many people with type 2 diabetes have complications present at diagnosis. Non-diabetic hyperglycaemia is a condition where blood glucose levels are elevated beyond normal but not high enough to be diagnosed with diabetes. Those with non-diabetic hyperglycaemia are at high risk of develo** type 2 diabetes. Data from robust clinical trials show that earlier treatment for type 2 diabetes may improve outcomes and that diabetes can be prevented in those with non-diabetic hyperglycaemia through lifestyle change; therefore, early identification is required. Uptake to routine health checks is low. Non-invasive risk assessments for diabetes offer a quick and easy way to detect those at high risk of these conditions and to target definitive testing whilst also engaging individuals with their risk factors. Such assessments use non-invasive risk factors to assess risk and can be used within routine care or opportunistically. Using such risk assessments is recommended by NICE to detect those at risk of diabetes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
EUR 29.95
Price includes VAT (Germany)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
EUR 93.08
Price includes VAT (Germany)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
EUR 117.69
Price includes VAT (Germany)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info
Hardcover Book
EUR 160.49
Price includes VAT (Germany)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Diabetes UK. Diabetes in the UK 2010: Key statistics on diabetes. 2010.

    Google Scholar 

  2. IDF. Diabetes Atlas Eighth Edition. 2017. http://www.diabetesatlas.org/.

  3. Harris MI, et al. Onset of NIDDM occurs at least 4–7 yr before clinical diagnosis. Diabetes Care. 1992;15(7):815–9.

    Article  PubMed  Google Scholar 

  4. Pierce MB, et al. Undiagnosed diabetes—data from the English longitudinal study of ageing. Diabet Med. 2009;26(7):679–85.

    Article  PubMed  Google Scholar 

  5. Griffin SJ, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet. 2011;378(9786):156–67.

    Article  PubMed  PubMed Central  Google Scholar 

  6. World Health Organisation. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus. Geneva: World Health Organisation; 2011.

    Google Scholar 

  7. Morris DH, et al. Progression rates from HbA1c 6.0–6.4% and other prediabetes definitions to type 2 diabetes: a meta-analysis. Diabetologia. 2013;56(7):1489–93.

    Article  PubMed  Google Scholar 

  8. National Cardiovascular Intelligence Network (NCVIN). NHS Diabetes Prevention Programme (NHS DPP) Non-diabetic hyperglycaemia. 2015. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/456149/Non_diabetic_hyperglycaemia.pdf.

  9. Gillies CL, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ. 2007;334:299.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Diabetes UK. The cost of diabetes. 2014. https://www.diabetes.org.uk/resources-s3/2017-11/diabetes%20uk%20cost%20of%20diabetes%20report.pdf.

  11. Hex N, et al. Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med. 2012;29(7):855–62.

    Article  PubMed  Google Scholar 

  12. Tunceli K, et al. The impact of Diabetes on employment and work productivity. Diabetes Care. 2005;28(11):2662–7.

    Article  PubMed  Google Scholar 

  13. American Diabetes Association. Economic costs of diabetes in the US in 2012. Diabetes Care. 2013;36(4):1033–46.

    Article  PubMed Central  Google Scholar 

  14. Nichols GA, Arondekar B, Herman WH. Medical care costs one year after identification of hyperglycemia below the threshold for diabetes. Med Care. 2008;46:287–92.

    Article  PubMed  Google Scholar 

  15. Herman WH. The economics of diabetes prevention. Med Clin. 2011;95(2):373–84.

    Google Scholar 

  16. Waugh N, et al. Screening for type 2 diabetes: literature review and economic modelling. Health Technol Assess. 2007;11(17):144.

    Article  Google Scholar 

  17. Erlinger TP, Brancati FL. Postchallenge hyperglycemia in a national sample of U.S. adults with type 2 diabetes. Diabetes Care. 2001;24(10):1734–8.

    Article  PubMed  Google Scholar 

  18. Davidson MB, Peters AL, Schriger DL. An alternative approach to the diagnosis of diabetes with a review of the literature. Diabetes Care. 1995;18(7):1065–71.

    Article  PubMed  Google Scholar 

  19. Waugh N, et al. Screening for type 2 diabetes: a short report for the National Screening Committee. Health Technol Assess. 2013;17(35):1–90.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Gallagher EJ, Bloomgarden ZT, Roith D. Review of hemoglobin A1c in the management of diabetes. J Diabetes. 2009;1(1):9–17.

    Article  PubMed  Google Scholar 

  21. Herman WH, Ma Y, Uwaifo G. Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the diabetes prevention program. Diabetes Care. 2007;30(10):2453–7.

    Article  PubMed  Google Scholar 

  22. Mostafa SA, et al. Independent effect of ethnicity on Glycemia in south Asians and white Europeans. Diabetes Care. 2012;35(8):1746–8.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Mostafa SA, et al. The potential impact of using glycated haemoglobin, HbA1c, as the preferred diagnostic tool for type 2 diabetes mellitus. Diabet Med. 2010;72:762–9.

    Article  Google Scholar 

  24. Gray LJ, Khunti K. Type 2 diabetes risk prediction—do biomarkers increase detection? Diabetes Res Clin Pract. 2013;101(3):245–7.

    Article  PubMed  Google Scholar 

  25. Khunti K, et al. A comparison of cost per case detected of screening strategies for type 2 diabetes and impaired glucose regulation: modelling study. Diabetes Res Clin Pract. 2012;97(3):505–13.

    Article  PubMed  Google Scholar 

  26. Buijsse B, et al. Risk assessment tools for identifying individuals at risk of develo** type 2 diabetes. Epidemiol Rev. 2011;33(1):46–62.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Collins GS, et al. Develo** risk prediction models for type 2 diabetes: a systematic review of methodology and reporting. BMC Med. 2011;9:103.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Noble D, et al. Risk models and scores for type 2 diabetes: systematic review. BMJ. 2011;343:d7163.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Barber SR, et al. Risk assessment tools for detecting those with pre-diabetes: a systematic review. Diabetes Res Clin Pract. 2014;105(1):1–13. https://doi.org/10.1016/j.diabres.2014.03.007. Epub 2014 Mar 18.

  30. Lindström J, Tuomilehto J. The Diabetes risk score. Diabetes Care. 2003;26(3):725–31.

    Article  PubMed  Google Scholar 

  31. Saaristo T, et al. Cross-sectional evaluation of the Finnish Diabetes risk score: a tool to identify undetected type 2 diabetes, abnormal glucose tolerance and metabolic syndrome. Diab Vasc Dis Res. 2005;2(2):67–72.

    Article  PubMed  Google Scholar 

  32. Cos FX, et al. Screening for people with abnormal glucose metabolism in the European DE-PLAN project. Diabetes Res Clin Pract. 2015;109(1):149–56.

    Article  PubMed  Google Scholar 

  33. Al-Lawati JA, Tuomilehto J. Diabetes risk score in Oman: a tool to identify prevalent type 2 diabetes among Arabs of the Middle East. Diabetes Res Clin Pract. 2007;77(3):438–44.

    Article  PubMed  Google Scholar 

  34. Chien K, et al. A prediction model for type 2 diabetes risk among Chinese people. Diabetologia. 2009;52(3):443–50.

    Article  PubMed  Google Scholar 

  35. Glümer C, et al. Risk scores for type 2 Diabetes can be applied in some populations but not all. Diabetes Care. 2006;29(2):410–4.

    Article  PubMed  Google Scholar 

  36. Griffin SJ, et al. Diabetes risk score: towards earlier detection of type 2 diabetes in general practice. Diabetes Metab Res Rev. 2000;16(3):164–71.

    Article  PubMed  Google Scholar 

  37. Gray LJ, et al. The Leicester risk assessment score for detecting undiagnosed type 2 diabetes and impaired glucose regulation for use in a multiethnic UK setting. Diabet Med. 2010;27(8):887–95.

    Article  PubMed  Google Scholar 

  38. Gray LJ, et al. Detection of impaired glucose regulation and/or type 2 diabetes mellitus, using primary care electronic data, in a multiethnic UK community setting. Diabetologia. 2012;55(4):959–66.

    Article  PubMed  Google Scholar 

  39. Hippisley-Cox J, et al. Predicting risk of type 2 diabetes in England and Wales: prospective derivation and validation of QDScore. Br Med J. 2009;388:b880.

    Article  Google Scholar 

  40. Hippisley-Cox J, Coupland C. Development and validation of QDiabetes-2018 risk prediction algorithm to estimate future risk of type 2 diabetes: cohort study. BMJ. 2017;359:j5019.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Webb DR, et al. Rationale and design of the ADDITION-Leicester study, a systematic screening programme and randomised controlled trial of multi-factorial cardiovascular risk intervention in people with type 2 diabetes mellitus detected by screening. Trials. 2010;11:16.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Willis A, et al. A community faith centre based screening and educational intervention to reduce the risk of type 2 diabetes: a feasibility study. Diabetes Res Clin Pract. 2016;120:73–80.

    Article  PubMed  Google Scholar 

  43. Gray LJ, et al. External validation of two diabetes risk scores in a young UK South Asian population. Diabetes Res Clin Pract. 2014;104(3):451–8.

    Article  PubMed  Google Scholar 

  44. Dunkley AJ, et al. Screening for glucose intolerance and development of a lifestyle education programme for prevention of type 2 diabetes in a population with intellectual disabilities: the STOP Diabetes research project. Southampton (UK): NIHR Journals Library; 2017. (Programme Grants for Applied Research, No. 5.11).

    Google Scholar 

  45. Barber S, et al. Prospective validation of the Leicester/Diabetes UK risk assessment for diagnosis of Type 2 diabetes. In Diabetes UK. Glasgow: Diabetic Medicine; 2016.

    Google Scholar 

  46. Chatterton H, et al. Risk identification and interventions to prevent type 2 diabetes in adults at high risk: summary of NICE guidance. BMJ. 2012;12(345):e4624.

    Article  Google Scholar 

  47. Patel N, et al. Develo** a conceptually equivalent type 2 diabetes risk score for Indian Gujaratis in the UK. J Diab Res. 2016;2016:9.

    Google Scholar 

  48. Hippisley-Cox J, Coupland C, Brindle P. The performance of seven QPrediction risk scores in an independent external sample of patients from general practice: a validation study. BMJ Open. 2014;4(8):e005809.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Collins GS, Altman DG. External validation of QDSCORE® for predicting the 10-year risk of develo** type 2 diabetes. Diabet Med. 2011;28(5):599–607.

    Article  PubMed  Google Scholar 

  50. National Cardiovascular Intelligence Network (NCVIN). NHS Diabetes Prevention Programme (NHS DPP) Non-diabetic hyperglycaemia. Public Health England. 2015. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/456149/Non_diabetic_hyperglycaemia.pdf.

  51. Robson J, et al. The NHS health check in England: an evaluation of the first 4 years. BMJ Open. 2016;6(1):e008840.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Smith S, Waterall J, Burden ACF. An evaluation of the performance of the NHS health check programme in identifying people at high risk of develo** type 2 diabetes. BMJ Open. 2013;3(3):e002219.

    Article  PubMed  PubMed Central  Google Scholar 

  53. NICE. Type 2 diabetes: prevention in people at high risk. Public health guideline [PH38]. 2017.

    Google Scholar 

  54. Sandbaek A, et al. Stepwise screening for diabetes identifies people with high but modifiable coronary heart disease risk. The ADDITION study. Diabetologia. 2008;51(7):1127–34.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Tao L, et al. Cost-effectiveness of intensive multifactorial treatment compared with routine care for individuals with screen-detected type 2 diabetes: analysis of the ADDITION-UK cluster-randomized controlled trial. Diabet Med. 2015;32(7):907–19.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Sandbæk A, et al. Effect of early multifactorial therapy compared with routine care on microvascular outcomes at 5 years in people with screen-detected diabetes: a randomized controlled trial. The ADDITION-Europe Study. Diabetes Care. 2014;37(7):2015–23.

    Article  PubMed  Google Scholar 

  57. Herman WH, et al. Early detection and treatment of type 2 diabetes reduce cardiovascular morbidity and mortality: a simulation of the results of the Anglo-Danish-Dutch study of intensive treatment in people with screen-detected diabetes in primary care (ADDITION-Europe). Diabetes Care. 2015;38(8):1449–55.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Gillies CL, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ. 2007;334:299.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Knowler WC, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.

    Article  PubMed  Google Scholar 

  60. Troughton J, et al. Development of a lifestyle intervention using the MRC framework for diabetes prevention in people with impaired glucose regulation. J Public Health (Oxf). 2016;38(3):​493–501. Epub 2015 Aug 25.

    Google Scholar 

  61. Davies MJ, et al. A community based primary prevention programme for type 2 diabetes integrating identification and lifestyle intervention for prevention: the let’s prevent Diabetes cluster randomised controlled trial. Prev Med. 2016;84:48–56.

    Article  PubMed  Google Scholar 

  62. Gray LJ, et al. Engagement, retention, and progression to type 2 diabetes: a retrospective analysis of the cluster-randomised “Let’s Prevent Diabetes” trial. PLoS Med. 2016;13(7):e1002078.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Leal J, et al. Cost-effectiveness of a pragmatic structured education intervention for the prevention of type 2 diabetes: economic evaluation of data from the let’s prevent diabetes cluster-randomised controlled trial. BMJ Open. 2017;7(1):e013592.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Lascar N, et al. Type 2 diabetes in adolescents and young adults. Lancet Diabetes Endocrinol. 2018;6(1):69–80. https://doi.org/10.1016/S2213-8587(17)30186-9. Epub 2017 Aug 25.

  65. Dabelea D, et al. Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA. 2014;311(17):1778–86.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Holden S, et al. The incidence of type 2 diabetes in the United Kingdom from 1991 to 2010. Diabetes Obes Metab. 2013;15(9):844–52.

    Article  PubMed  Google Scholar 

  67. Candler TP, et al. Continuing rise of type 2 diabetes incidence in children and young people in the UK. Diabet Med. 2018;35(6):737–44.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Wilmot E, Idris I. Early onset type 2 diabetes: risk factors, clinical impact and management. Ther Adv Chronic Dis. 2014;5(6):234–44.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Wilmot EG, et al. Prevalence of diabetes and impaired glucose metabolism in younger ‘at risk’ UK adults: insights from the STAND programme of research. Diabet Med. 2013;30(6):671–5.

    Article  PubMed  Google Scholar 

  70. The Lancet. Type 2 diabetes: the urgent need to protect young people. Lancet. 2018;392.

    Google Scholar 

  71. Eborall H, et al. Patients’ experiences of screening for type 2 diabetes: prospective qualitative study embedded in the ADDITION (Cambridge) randomised controlled trial. BMJ. 2007;335(7618):490.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Willis AW. The effectiveness of screening for type 2 diabetes within a community pharmacy setting, in Department of Health Sciences. University of Leicester; 2015.

    Google Scholar 

  73. Twigg MJ, et al. Community pharmacy type 2 diabetes risk assessment: demographics and risk results. Int J Pharm Pract. 2015;23(1):80–2.

    Article  PubMed  Google Scholar 

  74. George PM, et al. Screening for type 2 diabetes in the accident and emergency department. Diabet Med. 2005;22(12):1766–9.

    Article  PubMed  Google Scholar 

  75. Gomez-Peralta F, et al. Point-of-care capillary HbA1c measurement in the emergency department: a useful tool to detect unrecognized and uncontrolled diabetes. Int J Emerg Med. 2016;9(1):1–6.

    Article  Google Scholar 

  76. Hng T-M, et al. Diabetes case finding in the emergency department, using HbA1c: an opportunity to improve diabetes detection, prevention, and care. BMJ Open Diabetes Res Care. 2016;4(1).

    Google Scholar 

  77. NHS Dental Statistics. NHS Dental Statistics for England, 2017–18, Second quarterly report. NHS Digital 2018.

    Google Scholar 

  78. Preshaw PM, et al. Periodontitis and diabetes: a two-way relationship. Diabetologia. 2012;55(1):21–31.

    Article  PubMed  Google Scholar 

  79. Lalla E, et al. Identification of unrecognized diabetes and pre-diabetes in a dental setting. J Dent Res. 2011;90(7):855–60.

    Article  PubMed  Google Scholar 

  80. AlGhamdi AST, et al. Dental clinics as potent sources for screening undiagnosed diabetes and prediabetes. Am J Med Sci. 2013;345(4):331–4.

    Article  PubMed  Google Scholar 

  81. Genco RJ, et al. Screening for diabetes mellitus in dental practices: a field trial. J Am Dent Assoc. 2014;145(1):57–64.

    Article  PubMed  Google Scholar 

  82. Yonel Z, et al. Patients’ attendance patterns to different healthcare settings and perceptions of stakeholders regarding screening for chronic, non-communicable diseases in high street dental practices and community pharmacy: a cross-sectional study. BMJ Open. 2018;8(11):e024503.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Health Sciences, University of Leicester, Leicester, UK

    Laura J. Gray

Authors
  1. Laura J. Gray
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Laura J. Gray .

Editor information

Editors and Affiliations

  1. The University of Birmingham, School of Dentistry, Institute Of Clinical Sciences, College of Medical and Dental Sciences, Birmingham, UK

    Iain L.C. Chapple

  2. College of Dental Medicine, Division of Periodontics, Section of Oral, Diagnostic and Rehabilitation Sciences, New York, NY, USA

    Panos N. Papapanou

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Gray, L.J. (2020). Risk Assessment for Diabetes. In: Chapple, I., Papapanou, P. (eds) Risk Assessment in Oral Health. Springer, Cham. https://doi.org/10.1007/978-3-030-38647-4_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-38647-4_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-38646-7

  • Online ISBN: 978-3-030-38647-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation